PMC5742439_01
Clinical course of patient (Hb, T-Bil, and ID-Bil). T-Bil: total bilirubin; ID-Bil: indirect bilirubin.
CRIHEP2017-8793895.001.jpg
PMC5742439_01_CRIHEP2017-8793895.001.jpg
fig1
ITPA genotype showed SNP CA (rs7270101) as minor allele heterozygous. The clinical treatment progress is as follows (Figures 1 and 2). Initial treatment with Peg-IFN-alpha 2b 80 mug/week and RBV 400 mg/day was started in our hospital in March of 2007.
Clinical course of patient (ALT and HCV RNA). *Limit of detection (LOD).
CRIHEP2017-8793895.002.jpg
PMC5742439_01_CRIHEP2017-8793895.002.jpg
fig2
ITPA genotype showed SNP CA (rs7270101) as minor allele heterozygous. The clinical treatment progress is as follows (Figures 1 and 2). Initial treatment with Peg-IFN-alpha 2b 80 mug/week and RBV 400 mg/day was started in our hospital in March of 2007.
The variation of hemoglobin value with SOF and RBV combination therapy. Sofosbuvir dose was 400 mg/day.
CRIHEP2017-8793895.003.jpg
PMC5742439_01_CRIHEP2017-8793895.003.jpg
fig3
SOF/RBV combination therapy are shown in Table 1. Since her Hb level decreased gradually, the RBV dose was reduced from 600 to 400 mg/day at 4 weeks (Figure 3).
The variation of reticulocyte count during treatment with IFN and RBV combination therapy in this case and median of another 102 patients treated by our hospital.
CRIHEP2017-8793895.004.jpg
PMC5742439_01_CRIHEP2017-8793895.004.jpg
fig4
And, in spite of anemia, the reticulocyte count did not respond to the stimuli; it was very low during this treatment in this case (Figure 4).